['migraine prophylaxis']
['fremanezumab', 'placebo']

        Inclusion Criteria:

          -  The participant has a diagnosis of migraine with onset at ≤50 years of age.

          -  Body weight ≥45 kilograms.

          -  The participant has a history of migraine for ≥12 months prior to screening.

          -  Women of childbearing potential (WOCBP) whose male partners are potentially fertile
             (that is; no vasectomy) must use highly effective birth control methods for the
             duration of the study and the follow-up period and for 6.0 months after
             discontinuation of investigational medicinal product (IMP)

          -  Men must be sterile, or if they are potentially fertile/reproductively competent (not
             surgically [that is; vasectomy] or congenitally sterile) and their female partners are
             of childbearing potential, must use, together with their female partners, acceptable
             birth control methods for the duration of the study and for 6.0 months after
             discontinuation of the investigational medicinal product (IMP).

               -  Additional criteria apply, please contact the investigator for more information.

        Exclusion Criteria:

          -  At the time of screening visit, participant is receiving any preventive migraine
             medications, regardless of the medical indication for more than 5 days and expects to
             continue with these medications.

          -  Participant has received onabotulinumtoxinA for migraine or for any medical or
             cosmetic reasons requiring injections in the head, face, or neck during the 3 months
             before screening visit.

          -  The participant has used an intervention/device (for example; scheduled nerve blocks
             and transcranial magnetic stimulation) for migraine during the 2 months prior to
             screening.

          -  The participant uses triptans/ergots as preventive therapies for migraine.

          -  Participant uses non-steroidal anti-inflammatory drugs (NSAIDs) as preventive therapy
             for migraine on nearly daily basis for other indications. Note: Low dose aspirin (for
             example; 81 mg) used for cardiovascular disease prevention is allowed.

               -  Additional criteria apply, please contact the investigator for more information.
      